文献速递糖尿病

teplizumab治疗1型糖尿病:诊断后7年临床与免疫随访

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
PubMed 文献 · Diabetologia · 2018-12-19

AbATE试验评估teplizumab(一种Fc受体非结合人源化抗CD3单克隆抗体)治疗新发1型糖尿病,2011年结束。对平均随访7年的受试者分析显示,药物应答者C肽下降减少且持续存在免疫学应答,但C肽改善未伴随HbA1c或胰岛素用量降低。

要点

  • 药物应答者随访时C肽下降显著减少,但HbA1c与胰岛素用量未见改善
  • 药物应答者随访时PD-1阳性中央记忆与无反应性CD8+ T细胞频率显著增加
  • 平均随访7年提示teplizumab应答者存在持久免疫学效应

核心结论

  • teplizumab应答者在糖尿病诊断后长达7年仍显示C肽下降减少和持续免疫学应答。

研究设计与样本

  • C肽通过4小时混合餐耐量试验评估,检测自身抗体、HbA1c,胰岛素用量取自患者记录。
  • 外周血单个核细胞通过流式细胞术和细胞因子释放分析。

主要发现

  • 药物组与对照组总体混合餐耐量试验C肽应答相似,但1年时识别的药物应答者C肽下降显著减少。
  • C肽应答改善未伴随HbA1c水平或胰岛素用量降低。
  • 药物应答者随访时程序性细胞死亡蛋白1阳性中央记忆和无反应性CD8+ T细胞频率显著增加。

临床怎么用

  • 对teplizumab应答的新发1型糖尿病患者,长期随访中可关注C肽保留情况与免疫学指标变化。

局限性

  • C肽改善未转化为HbA1c或胰岛素用量的临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The long-term effects of successful immune therapies for treatment of type 1 diabetes have not been well studied. The Autoimmunity-Blocking Antibody for Tolerance (AbATE) trial evaluated teplizumab, an Fc receptor non-binding humanised anti-CD3 monoclonal antibody in individuals with new-onset type 1 diabetes, and ended in 2011. Clinical drug-treated responders showed an increased frequency of 'partially exhausted' CD8+ T cells. We studied the clinical, immunological and metabolic status of participants after an average follow-up of 7 years. METHODS: Participants with detectable C-peptide at year 2 of AbATE returned for follow-up. C-peptide responses were assessed by 4 h mixed-meal tolerance test. Autoantibodies and HbA1c levels were measured and average daily insulin use was obtained from patient logs. Peripheral blood mononuclear cells were analysed by flow cytometry and cytokine release. RESULTS: Fifty-six per cent of the original participants returned. Three of the original control group who did not return had lost all detectable C-peptide by the end of the 2 year trial. The C-peptide responses to a mixed-meal tolerance test were similar overall in the drug vs control group of participants but were significantly improved, with less loss of C-peptide, in drug-treated responders identified at 1 year. However, the improvements in C-peptide response were not associated with lower HbA1c levels or insulin use. Drug-treated responders showed a significantly increased frequency of programmed cell death protein 1-positive central memory and anergic CD8+ T cells at follow-up. CONCLUSIONS/INTERPRETATION: These findings suggest there is reduced decline in C-peptide and persistent immunological responses up to 7 years after diagnosis of diabetes in individuals who respond to teplizumab. TRIAL REGISTRATION: ClinicalTrials.gov NCT02067923; the protocol is available at www.immunetolerance.org (ITN027AI).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Perdigoto AL, Preston-Hurlburt P, Clark P, et al. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. 2018. PMID: 30569273. doi:10.1007/s00125-018-4786-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。